Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PPIA | P62937 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600049 | 0.87 | GPR3 (0.41) | GPR3KMT2APOLBCYP2D6SLC6A2 | |
| SCHEMBL31355068 | 0.87 | GPR3 (0.41) | GPR3KMT2APOLBCYP2D6SLC6A2 | |
| SCHEMBL27549930 | 0.82 | GPR3 (0.42) | GPR3KMT2APOLBCYP2D6SLC6A2 | |
| SCHEMBL3060295 | 0.81 | GPR3 (0.34) | GPR3KMT2APOLBCYP2D6SLC6A2 | |
| SCHEMBL27666697 | 0.81 | GPR3 (0.41) | GPR3KMT2APOLBCYP2D6SLC6A2 | |
| SCHEMBL948180 | 0.79 | SLC22A2 (0.40) | GPR3KMT2APOLBCYP2D6SLC6A2 | |
| SCHEMBL3202976 | 0.79 | KMT2A (0.40) | GPR3KMT2APOLBCYP2D6SLC6A2 | |
| SCHEMBL31355071 | 0.79 | KMT2A (0.40) | GPR3KMT2APOLBCYP2D6SLC6A2 | |
| SCHEMBL28900959 | 0.78 | CYP2D6 (0.39) | GPR3KMT2APOLBCYP2D6SLC6A2 | |
| SCHEMBL7389335 | 0.77 | SLC22A2 (0.38) | GPR3KMT2APOLBCYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247432-B2 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-21 | — | — | US | disclosed |
| US-20110224255-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | BRESLIN HENRY JOSEPH | 2011-09-15 | — | — | US | disclosed |
| US-7947713-B2 | (3-(4-phenyl-1H-imidazol-2-yl)-1,2,3,4-tetrahydro-isoquinoline; inactivation of endogenous neuropeptides such as cholecystokinis; eating disorders, obesity, psychotic syndromes and associated psychiatric disorders; chemical intermediates coupling | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20080108653-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | BRESLIN HENRY J | 2008-05-08 | — | — | US | disclosed |
| EP-1392291-B1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-05-30 | — | — | EP | disclosed |
| US-20060276509-A1 | Tripeptidyl peptidase inhibitors | BRESLIN HENRY J | 2006-12-07 | — | — | US | disclosed |
| US-7125891-B2 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-24 | — | — | US | disclosed |
| EP-1392291-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-03 | — | — | EP | disclosed |
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-19 | — | — | US | disclosed |
| WO-2002036116-A9 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002036116-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | GPR3 126/4885KMT2A 3544/4885POLB 4443/4885 |
| US-20080108653-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | CCKAR, CCKBR, VIP | GPR3 250/4885KMT2A 3763/4885POLB 4714/4885 |
| US-20110224255-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | CCKAR, CCKBR, VIP | GPR3 250/4885KMT2A 3763/4885POLB 4714/4885 |
| US-20060276509-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | GPR3 250/4885KMT2A 3763/4885POLB 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.